Oncothyreon Inc. said a test of its PX-866 anti-cancer drug was “effective” in a test related to heart disease.
At the American Thoracic Society International Conference in San Diego this week, Dr. William Hardie, an associate professor of pulmonary medicine at Children’s Hospital Medical Center in Cincinnati, said in his preclinical model test of pulmonary fibrosis, PX-866 “prevented both the deterioration in lung function and the fibrosis normally seen in the model.” He added that the results possibly indicate the drug “might be beneficial in such human lung diseases as idiopathic pulmonary fibrosis.”
Officials at the Seattle biotech (NASDAQ: ONTY) said although they’re currently focusing PX-866 on cancer, they’re “very interested” in the possibilities of its use “in non-malignant diseases, including autoimmune and cardiovascular diseases.”
Published in
No comments:
Post a Comment